Both KI Innovations and AstraZeneca are committed to growing and strengthening the Nordic Life Science sector. As part of this effort, KI Innovations has announced an exciting new collaboration with AstraZeneca Exchange Mentoring to help start-up companies access big pharma insights.

“This is a great opportunity for the start-ups at KI Innovations and we are pleased to enter this partnering program with AstraZeneca. We see clear benefits for our companies and projects as they are given the opportunity to utilize the expertise of AstraZeneca in a flexible structure and free of charge,” says Mats Ferm, Business Coach at KI Innovations.

The idea is to keep it simple. AstraZeneca mentors work with established incubators, such as KI Innovations, and respond to queries from linked companies. Mentors in turn offer insights to these companies on a wide range of topics, including trial design, diagnostics, digital health, medical devices, drug screening experiments, and commercial potential. Support is typically provided through one-time advisory sessions.

“Our goal is to focus where we can help to make a difference,” said Elisabeth Björk, AstraZeneca Senior Vice President, Late Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca. “We know that innovation does not happen in isolation. By collaborating with KI Innovations and other important incubators, we can share pharmaceutical industry knowledge and perspective with start-ups and early entrepreneurs in the region, and help them to move towards sustainable and successful growth.”

For more information about the collaboration, please contact
Mats Ferm: mats.ferm@kiinnovations.se